Increasing role for modified bismuth-containing quadruple therapies for Helicobacter pylori eradication.
作者信息
Graham David Y, Fagoonee Sharmila, Pellicano Rinaldo
机构信息
Department of Medicine, Michael E. DeBakey VAMC, Baylor College of Medicine, Houston, TX, USA.
Institute for Biostructures and Bioimages (CNR), Molecular Biotechnology Center, University of Turin, Turin, Italy.
出版信息
Minerva Gastroenterol Dietol. 2017 Jun;63(2):77-79. doi: 10.23736/S1121-421X.17.02369-8. Epub 2017 Jan 12.
Abstract
摘要
相似文献
1
Increasing role for modified bismuth-containing quadruple therapies for Helicobacter pylori eradication.改良含铋四联疗法在根除幽门螺杆菌中的作用日益增强。
Minerva Gastroenterol Dietol. 2017 Jun;63(2):77-79. doi: 10.23736/S1121-421X.17.02369-8. Epub 2017 Jan 12.
2
Comparison of three different second-line quadruple therapies including bismuth subcitrate in Turkish patients with non-ulcer dyspepsia who failed to eradicate Helicobacter pylori with a 14-day standard first-line therapy.在土耳其非溃疡性消化不良患者中，比较三种不同的含枸橼酸铋钾二线四联疗法，这些患者采用14天标准一线疗法未能根除幽门螺杆菌。
J Gastroenterol Hepatol. 2008 Jan;23(1):42-5. doi: 10.1111/j.1440-1746.2007.04984.x. Epub 2007 Jun 7.
3
Rescue therapy with bismuth-containing quadruple therapy in patients infected with metronidazole-resistant Helicobacter pylori strains.含铋的四联疗法对甲硝唑耐药的幽门螺杆菌感染患者的挽救治疗。
Clin Res Hepatol Gastroenterol. 2016 Sep;40(4):517-24. doi: 10.1016/j.clinre.2015.12.012. Epub 2016 Feb 2.
4
What is the impact of Helicobacter pylori density on the success of eradication therapy: a clinico-histopathological study.幽门螺杆菌密度对根除治疗成功率的影响：临床病理研究。
Clin Res Hepatol Gastroenterol. 2013 Dec;37(6):642-6. doi: 10.1016/j.clinre.2013.05.005. Epub 2013 Jun 21.
5
[Helicobacter pylori: what schemes of eradication are essential today?].[幽门螺杆菌：当今哪些根除方案至关重要？]
Ter Arkh. 2011;83(8):41-4.
6
Helicobacter pylori eradication in renal recipient: triple or quadruple therapy?肾移植受者幽门螺杆菌根除治疗：三联疗法还是四联疗法？
Acta Med Iran. 2014;52(4):271-4.
7
Bismuth-based quadruple therapy modified with moxifloxacin for Helicobacter pylori eradication.用莫西沙星改良的铋剂四联疗法根除幽门螺杆菌
Minerva Gastroenterol Dietol. 2017 Jun;63(2):80-84. doi: 10.23736/S1121-421X.16.02354-0. Epub 2016 Dec 14.
8
A Randomized Controlled Trial Shows that both 14-Day Hybrid and Bismuth Quadruple Therapies Cure Most Patients with Helicobacter pylori Infection in Populations with Moderate Antibiotic Resistance.一项随机对照试验表明，在抗生素耐药率中等的人群中，14 天的混合疗法和铋四联疗法都能治愈大多数幽门螺杆菌感染患者。
Antimicrob Agents Chemother. 2017 Oct 24;61(11). doi: 10.1128/AAC.00140-17. Print 2017 Nov.
9
A real life study of Helicobacter pylori eradication with bismuth quadruple therapy in naïve and previously treated patients.铋剂四联疗法根除初治及曾接受治疗患者幽门螺杆菌的真实生活研究。
Rev Esp Enferm Dig. 2017 Aug;109(8):552-558. doi: 10.17235/reed.2017.4809/2016.
10
Concomitant, bismuth quadruple, and 14-day triple therapy in the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial.一线治疗幽门螺杆菌感染中含铋四联、14 天三联疗法的比较：一项多中心、开放标签、随机试验。
Lancet. 2016 Nov 12;388(10058):2355-2365. doi: 10.1016/S0140-6736(16)31409-X. Epub 2016 Oct 18.
引用本文的文献
1
Efficacy and Safety of 10-Day Minocycline Twice Daily in Bismuth-Containing Quadruple Therapy as the First-Line Treatment of Infection: A Prospective Single-Arm Study.铋剂四联疗法中每日两次服用米诺环素10天作为幽门螺杆菌感染一线治疗的疗效和安全性：一项前瞻性单臂研究
JGH Open. 2025 Jul 28;9(8):e70233. doi: 10.1002/jgh3.70233. eCollection 2025 Aug.
2
Susceptibility-guided vs. empirical 10-day quadruple treatment for -infected patients: A prospective clinical trial of first-line therapy.易感性引导的治疗与经验性10天四联疗法治疗感染患者：一线治疗的前瞻性临床试验
Front Microbiol. 2022 Sep 7;13:973975. doi: 10.3389/fmicb.2022.973975. eCollection 2022.
3
Antibiotic resistance patterns of Helicobacter pylori strains isolated from the Tibet Autonomous Region, China.中国西藏自治区分离的幽门螺杆菌菌株的抗生素耐药模式。
BMC Microbiol. 2022 Aug 13;22(1):196. doi: 10.1186/s12866-022-02613-y.
4
diagnosis and therapy in the era of antimicrobial stewardship.抗菌药物管理时代的诊断与治疗
Therap Adv Gastroenterol. 2021 Dec 21;14:17562848211064080. doi: 10.1177/17562848211064080. eCollection 2021.
5
Is tailored therapy based on antibiotic susceptibility effective ? a multicenter, open-label, randomized trial.基于抗生素药敏的靶向治疗有效吗？一项多中心、开放标签、随机试验。
Front Med. 2020 Feb;14(1):43-50. doi: 10.1007/s11684-019-0706-8. Epub 2020 Jan 3.
6
Efficacy of dexlansoprazole-based triple therapy for infections.基于右兰索拉唑的三联疗法治疗感染的疗效。
Therap Adv Gastroenterol. 2019 Sep 5;12:1756284819870960. doi: 10.1177/1756284819870960. eCollection 2019.
7
Probiotic effect on attachment and inhibition of inflammation in human gastric epithelial cells.益生菌对人胃上皮细胞黏附及炎症抑制的作用
Exp Ther Med. 2019 Sep;18(3):1551-1562. doi: 10.3892/etm.2019.7742. Epub 2019 Jul 5.
8
Comment #2 on "First-Line Eradication with Vonoprazan, Clarithromycin, and Metronidazole in Patients Allergic to Penicillin".关于“对青霉素过敏患者使用沃克帕唑、克拉霉素和甲硝唑进行一线根除治疗”的评论2
Gastroenterol Res Pract. 2018 Dec 16;2018:5260358. doi: 10.1155/2018/5260358. eCollection 2018.
9
Efficacy and Safety of Wei Bi Mei, a Chinese Herb Compound, as an Alternative to Bismuth for Eradication of .胃铋镁，一种中药复方，作为铋剂替代物用于根除幽门螺杆菌的疗效和安全性。 （注：原文句末不完整，推测补充了“幽门螺杆菌”使句子完整通顺，以便准确翻译）
Evid Based Complement Alternat Med. 2018 Feb 5;2018:4320219. doi: 10.1155/2018/4320219. eCollection 2018.
本文引用的文献
1
Bismuth-based quadruple therapy modified with moxifloxacin for Helicobacter pylori eradication.用莫西沙星改良的铋剂四联疗法根除幽门螺杆菌
Minerva Gastroenterol Dietol. 2017 Jun;63(2):80-84. doi: 10.23736/S1121-421X.16.02354-0. Epub 2016 Dec 14.
2
A 2016 panorama of Helicobacter pylori infection: key messages for clinicians.2016年幽门螺杆菌感染全景：给临床医生的关键信息
Panminerva Med. 2016 Dec;58(4):304-317.
3
Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report.幽门螺杆菌感染的管理——马斯特里赫特 V/佛罗伦萨共识报告。
Gut. 2017 Jan;66(1):6-30. doi: 10.1136/gutjnl-2016-312288. Epub 2016 Oct 5.
4
Failed Eradication for Helicobacter pylori. What Should Be Done?幽门螺杆菌根除失败。该怎么办？
Dig Dis. 2016;34(5):505-9. doi: 10.1159/000445230. Epub 2016 Jun 22.
5
The Toronto Consensus for the Treatment of Helicobacter pylori Infection in Adults.《多伦多成人幽门螺杆菌感染治疗共识》。
Gastroenterology. 2016 Jul;151(1):51-69.e14. doi: 10.1053/j.gastro.2016.04.006. Epub 2016 Apr 19.
6
Helicobacter pylori therapy: a paradigm shift.幽门螺杆菌治疗：范式转变。
Expert Rev Anti Infect Ther. 2016 Jun;14(6):577-85. doi: 10.1080/14787210.2016.1178065. Epub 2016 May 3.
7
Role of bismuth in improving Helicobacter pylori eradication with triple therapy.铋在三联疗法提高幽门螺杆菌根除率中的作用。
Gut. 2016 May;65(5):870-8. doi: 10.1136/gutjnl-2015-311019. Epub 2016 Feb 4.
8
Hp-normogram (normo-graham) for Assessing the Outcome of H. pylori Therapy: Effect of Resistance, Duration, and CYP2C19 Genotype.用于评估幽门螺杆菌治疗结果的Hp正态概率图（正态-格雷厄姆图）：耐药性、疗程和CYP2C19基因型的影响
Helicobacter. 2016 Apr;21(2):85-90. doi: 10.1111/hel.12287. Epub 2015 Nov 27.
9
Bismuth, lansoprazole, amoxicillin and metronidazole or clarithromycin as first-line Helicobacter pylori therapy.铋剂、兰索拉唑、阿莫西林和甲硝唑或克拉霉素作为一线幽门螺杆菌治疗。
Gut. 2015 Nov;64(11):1715-20. doi: 10.1136/gutjnl-2015-309900. Epub 2015 Sep 2.
10
How to Effectively Use Bismuth Quadruple Therapy: The Good, the Bad, and the Ugly.如何有效使用铋剂四联疗法：优点、缺点与问题
Gastroenterol Clin North Am. 2015 Sep;44(3):537-63. doi: 10.1016/j.gtc.2015.05.003. Epub 2015 Jun 19.
Zotero 插件